ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Warm Autoimmune Hemolytic Anemia

In brief

The main objective of the study is to evaluate the safety and efficacy of ALXN1830 compared to placebo in adult participants with warm autoimmune hemolytic anemia (WAIHA).

Key facts

Study ID

NCT04256148

Run by

Alexion Pharmaceuticals, Inc.

People needed

0

Starts

2021-07-01

Expected to finish

2023-04-30

Last updated by the study team

2020-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Alexion Study Site — Whittier, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.